Seamless Therapeutics has a new CEO

Seamless Therapeutics recently announced two personnel changes. Dr Albert Seymour, a seasoned expert in the field of human genetics and pharmaceutical R&D, has been appointed as the new President and CEO, while Adam Rosenberg has been appointed independent Chairman of the Board. Both have an impressive track record in leading biotechnology companies, particularly in the areas of gene editing and new technologies.

The appointment comes against the backdrop of Seamless Therapeutics' progress in recombinase programming. The company's technology platform enables site-specific programmable recombinases for precise therapeutic gene editing. These developments have the potential to usher in a new era in the field of gene editing and address a significant unmet medical need.

The formation of Seamless Tx Inc. in Lexington, MA, will allow the company to focus on the further development of its differentiated recombinase technology. Dr Seymour will work from there, while Dr Anne-K. Heninger will continue to lead the operational business at the Dresden site.

The company has raised significant funding to date to advance its technology platform and develop a pipeline of innovative product candidates. These developments hold the promise of a new class of potentially curative therapies for patients worldwide.

All in all, these personnel changes and developments represent an exciting step for Seamless Therapeutics and the biotechnology industry as a whole.

Article from "Seamless Therapeutics" dated 23/04/2024